EUVIMEDEUVIMED entdecken
Crossref

The impact of CYP3A4 rs2242480 on oral lurasidone: A population pharmacokinetic model and exposure-efficacy analysis in Chinese bipolar depression patients

Chunxiao Dai, Meihua Lin, Nana Xu, Yaoyang Fu, Xuanwei Li, Yali Shi, Mian Wu, Yinbo Li, Jian Xie, Shaohua Hu, Qingwei Zhao

Journal of Affective Disorders · 2026

DOI: 10.1016/j.jad.2025.120588 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Affective Disorders, 2026. Verfasst von Chunxiao Dai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Psychology, Hangzhou First People's Hospital, Hangzhou, 310006, China. Hauptthemen laut MEDLINE: Antipsychotic Agents, Bipolar Disorder, Cytochrome P-450 CYP3A, Lurasidone Hydrochloride. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Primary Research and Development Plan of Zhejiang Province, Medical Science and Technology Project of Zhejiang Province, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study aims to develop a population pharmacokinetic (PPK) model and perform an exposure-efficacy analysis for lurasidone in patients with bipolar depression, thus interpretating the inter-individual variability in its pharmacokinetics and optimizing dosing regimens. METHODS: A PPK model and exposure-efficacy analysis were established in Chinese patients with bipolar depression. 241 lurasidone concentration measurments from 133 patients were included. Demographic information was collected and genotypes for CYP3A4 and HTR1A alleles were determined. Treatment efficacy was defined as the reduction in the Montgomery-Asberg Depression Rating Scale (MADRS) score at week 4. RESULTS: A one-compartment model with first-order kinetics for lurasidone was fitted. The apparent clearance (CL/F) of lurasidone was significantly lower in CYP3A4 rs2242480 CC carriers (330 L/h) than in TC (385 L/h) and TT (441 L/h) carriers, representing reductions of 14.3 % and 25.2 %, respectively. Additionally, CL/F was positively correlated with ideal body weight (IBW). Incorporating these covariates reduced the interindividual variability in CL/F from 40.5 % to 37.1 %. The exposure-efficacy analysis demonstrated a dose-denpedent increase in area under the curve (AUC), and MADRS score improved with an increasing AUC and reached a plateau at an AUC of approximately 167 mg·h·L-1, corresponding to an optimal daily dose range of 45-55 mg. CONCLUSION: The pharmacokinetics of lurasidone in patients with bipolar depression are significantly influenced by IBW and the rs2242480 genotype, enabling a practical framework for precision dosing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsBipolar DisorderCytochrome P-450 CYP3ALurasidone HydrochlorideAdultFemaleHumansMaleMiddle AgedAdministration, OralAllelesChinaGenotypePolymorphism, Single NucleotideTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

Bipolar depressionCYP3A4 rs2242480Exposure-efficacyLurasidonePopulation pharmacokinetics

Substanzen

Antipsychotic AgentsCYP3A4 protein, humanCytochrome P-450 CYP3ALurasidone Hydrochloride

Autor:innen und Institutionen

  • Department of Clinical Psychology, Hangzhou First People's Hospital, Hangzhou, 310006, China.
  • Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou, 31…
  • Third Hospital of Quzhou, Quzhou, 324000, China.
  • Department of Psychiatry, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
  • Third People's Hospital of Fuyang, Hangzhou, 311402, China.
  • Department of Clinical Psychology, Hangzhou First People's Hospital, Hangzhou, 310006, China. Electronic address: 20170002@zcmu.edu.cn.

Förderung

  • Primary Research and Development Plan of Zhejiang Province
  • Medical Science and Technology Project of Zhejiang Province
  • National Key Research and Development Program of China

Zitieren

APA

Dai, C., Lin, M., Xu, N., Fu, Y., Li, X., Shi, Y., Wu, M., Li, Y., Xie, J., Hu, S., & Zhao, Q. (2026). The impact of CYP3A4 rs2242480 on oral lurasidone: A population pharmacokinetic model and exposure-efficacy analysis in Chinese bipolar depression patients. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.120588

Vancouver

Dai C, Lin M, Xu N, Fu Y, Li X, Shi Y, et al. The impact of CYP3A4 rs2242480 on oral lurasidone: A population pharmacokinetic model and exposure-efficacy analysis in Chinese bipolar depression patients. Journal of Affective Disorders. 2026. doi:10.1016/j.jad.2025.120588

BibTeX
@article{Dai2026,
  author = {Dai, Chunxiao and Lin, Meihua and Xu, Nana and Fu, Yaoyang and Li, Xuanwei and Shi, Yali and Wu, Mian and Li, Yinbo and Xie, Jian and Hu, Shaohua and Zhao, Qingwei},
  title = {The impact of CYP3A4 rs2242480 on oral lurasidone: A population pharmacokinetic model and exposure-efficacy analysis in Chinese bipolar depression patients},
  journal = {Journal of Affective Disorders},
  year = {2026},
  doi = {10.1016/j.jad.2025.120588}
}
Kostenlos starten →